Matthew L. Posard - Net Worth and Insider Trading

Matthew L. Posard Net Worth

The estimated net worth of Matthew L. Posard is at least $8 Million dollars as of 2024-12-27. Matthew L. Posard is the Sr VP & General Manager of Illumina Inc and owns about 30,858 shares of Illumina Inc (ILMN) stock worth over $4 Million. Matthew L. Posard is the Director of Halozyme Therapeutics Inc and owns about 69,874 shares of Halozyme Therapeutics Inc (HALO) stock worth over $3 Million. Matthew L. Posard is also the Director of Nautilus Biotechnology Inc and owns about 150,000 shares of Nautilus Biotechnology Inc (NAUT) stock worth over $264,000. Besides these, Matthew L. Posard also holds Talis Biomedical Corp (TLIS) , DermTech Inc (DMTKQ) . Details can be seen in Matthew L. Posard's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew L. Posard has not made any transactions after 2024-08-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Matthew L. Posard

To

Matthew L. Posard Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew L. Posard owns 7 companies in total, including DermTech Inc (CNACU) , Halozyme Therapeutics Inc (HALO) , and Cardiff Oncology Inc (CRDF) among others .

Click here to see the complete history of Matthew L. Posard’s form 4 insider trades.

Insider Ownership Summary of Matthew L. Posard

Ticker Comapny Transaction Date Type of Owner
CNACU DermTech Inc 2020-06-17 director
HALO Halozyme Therapeutics Inc 2024-08-14 director
CRDF Cardiff Oncology Inc 2015-08-21 Chief Commercial Officer
LIMIT LIMIT 2013-05-30 Sr VP & GM & Consumer Genomics
LIMIT LIMIT 2021-02-17 director
LIMIT LIMIT 2021-01-11 director
LIMIT LIMIT 2021-12-01 director

Matthew L. Posard Latest Holdings Summary

Matthew L. Posard currently owns a total of 5 stocks. Among these stocks, Matthew L. Posard owns 30,858 shares of Illumina Inc (ILMN) as of May 30, 2013, with a value of $4 Million and a weighting of 53.52%. Matthew L. Posard owns 69,874 shares of Halozyme Therapeutics Inc (HALO) as of August 14, 2024, with a value of $3 Million and a weighting of 43%. Matthew L. Posard also owns 150,000 shares of Nautilus Biotechnology Inc (NAUT) as of December 1, 2021, with a value of $264,000 and a weighting of 3.39%. The other 2 stocks Talis Biomedical Corp (TLIS) , DermTech Inc (DMTKQ) have a combined weighting of 0.09% among all his current holdings.

Latest Holdings of Matthew L. Posard

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ILMN Illumina Inc 2013-05-30 30,858 135.18 4,171,384
HALO Halozyme Therapeutics Inc 2024-08-14 69,874 47.96 3,351,157
NAUT Nautilus Biotechnology Inc 2021-12-01 150,000 1.76 264,000
TLIS Talis Biomedical Corp 2021-02-17 4,167 1.70 7,084
DMTKQ DermTech Inc 2021-01-11 86,863 0.00 0

Holding Weightings of Matthew L. Posard


Matthew L. Posard Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew L. Posard has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 2,836 shares on May 30, 2013, which brought Matthew L. Posard around $200,789.

According to the SEC Form 4 filings, Matthew L. Posard has made a total of 3 transactions in Halozyme Therapeutics Inc (HALO) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Halozyme Therapeutics Inc is the sale of 29,881 shares on August 14, 2024, which brought Matthew L. Posard around $2 Million.

According to the SEC Form 4 filings, Matthew L. Posard has made a total of 1 transactions in Nautilus Biotechnology Inc (NAUT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Nautilus Biotechnology Inc is the acquisition of 50,000 shares on December 1, 2021, which cost Matthew L. Posard around $225,500.

More details on Matthew L. Posard's insider transactions can be found in the Insider Trading History of Matthew L. Posard table.

Insider Trading History of Matthew L. Posard

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew L. Posard Trading Performance

GuruFocus tracks the stock performance after each of Matthew L. Posard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew L. Posard is -8.44%. GuruFocus also compares Matthew L. Posard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew L. Posard within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Matthew L. Posard's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Matthew L. Posard

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 27.93 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 24.67 LIMIT LIMIT LIMIT LIMIT LIMIT

Matthew L. Posard Ownership Network

Ownership Network List of Matthew L. Posard

No Data

Ownership Network Relation of Matthew L. Posard

Insider Network Chart

Matthew L. Posard Owned Company Details

What does DermTech Inc do?

Who are the key executives at DermTech Inc?

Matthew L. Posard is the director of DermTech Inc. Other key executives at DermTech Inc include Chief Commercial Officer Todd Michael Wood , director & Chief Executive Officer John Dobak , and Chief Operating Officer Claudia Ibarra .

DermTech Inc (CNACU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DermTech Inc (CNACU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DermTech Inc (CNACU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DermTech Inc (CNACU)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

DermTech Inc Insider Transactions

No Available Data

Matthew L. Posard Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew L. Posard. You might contact Matthew L. Posard via mailing address: 11099 N. Torrey Pines Road, Suite 100, La Jolla Ca 92037.

Discussions on Matthew L. Posard

No discussions yet.